Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus cetuximab for recurrent/metastatic head and neck cancer after pembrolizumab
2019-003114-13Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Medical University of Vienna. Primary endpoints: Confirmed overall response rate (ORR), Best overall response and 4 more. Started Nov 2019; status: completed.
02
Drugs
cetuximabpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-003114-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003114-13.